Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Relmada Therapeutics
Biotech
After 3rd phase 3 strike, Relmada's depression drug is out
The biotech is looking into a broad range of paths forward, including a merger or reverse merger, buying or selling assets, or selling the company.
Darren Incorvaia
Dec 9, 2024 2:30pm
Scorpion taps new CEO, CMO—Chutes & Ladders
Jan 5, 2024 9:30am
Relmada's depression med bounces back in open-label trial
Sep 20, 2023 11:00am
After phase 3 flops, Relmada plots depression drug comeback
Mar 24, 2023 5:51am
Biotech pipeline hosts 163 potential meds for mental illness
Jan 30, 2023 5:30am
Fierce Biotech's Rotten Tomatoes of 2022
Dec 19, 2022 3:00am
